Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.78 |
| ▸ | TEK | Q02763 | 13/20 | 0.78 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw673715X SCHEMBL5342162 | 0.95 | KDR (0.86) | KDRTEK | |
| SCHEMBL5350261 | 0.90 | KDR (0.70) | KDRTEKLMNAMAPK1HIF1A | |
| SCHEMBL5349129 | 0.89 | KDR (0.74) | KDRTEK | |
| SCHEMBL5341929 | 0.87 | KDR (0.78) | KDRTEK | |
| SCHEMBL5346860 | 0.87 | KDR (0.78) | KDRTEK | |
| SCHEMBL14444807 | 0.87 | KDR (0.62) | KDRTEK | |
| SCHEMBL14375465 | 0.87 | KDR (0.78) | KDRTEK | |
| SCHEMBL5357664 | 0.87 | KDR (0.62) | KDRTEKABL1 | |
| SCHEMBL5344982 | 0.87 | KDR (0.78) | KDRTEK | |
| SCHEMBL5345796 | 0.86 | KDR (0.73) | KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | claimed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | claimed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | claimed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-20070249600-A1 | CHEMICAL COMPOUNDS | CHEUNG MUI | 2007-10-25 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238813-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20040082583-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249600-A1 | CHEMICAL COMPOUNDS | TIE1, KDR, FLT4 | KDR 2/4885TEK 5/4885ABL1 9/4885 |
| US-20040082583-A1 | Chemical compounds | TIE1, KDR, FLT4 | KDR 2/4885TEK 5/4885ABL1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.